The prevalence of Growth Hormone Deficiency in Autoimmune Thyroid Disease.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON22746

Enrollment

600

Registered

2006-08-28

Start date

2006-08-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune hypothyroidism treated with thyroxine

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Autoimmune hypothyroidism Adequate thyroxine treatment

Exclusion criteria

Exclusion criteria: 1. History of hypothalamic or pituitary disease or known growth hormone deficiency 2. Pregnancy 3. Hypothyroidism after treatment for Graves' disease or surgery or I131 4. Major concurrent diseases 5. Use of medications known to interfere with the growth hormone-IGF-1 axis 6. No informed consent 7. Alcohol or drug abuse

Design outcomes

Primary

Measure	Time frame
Prevalence of growth hormone deficiency in patients with autoimmune hypothyroidism	—

Secondary

Measure	Time frame
Quality of Life in patients with autoimmune hypothyroidism with or without growth hormone deficiency	—

Contacts

Public ContactS.A. Eskes

Academic Medical Center (AMC), Department of Endocrinology, P.O. Box 22660

S.A.Eskes@amc.uva.nl+31 (0)20 5669111

Outcome results